Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myovant Ready To File Relugolix For Prostate Cancer

Executive Summary

Secondary endpoint assessing cardiovascular risk may offer important differentiation from AbbVie’s Lupron. Myovant accelerated the prostate cancer filing soon after slowing the planned relugolix submission for uterine fibroids.

You may also be interested in...



Gene Therapy 'Vant' Unveiled As Dainippon, Roivant Finalize $3bn Deal

Japanese firm signs definitive agreement to acquire Roivant's interests in five 'vants' initially, including new gene therapy operation, as ex-Genentech president named head of new entity.

AbbVie Revs Up The Race To Market In Uterine Fibroids

AbbVie and Neurocrine submitted an NDA to FDA for elagolix for bleeding associated with uterine fibroids, leading in what is expected to be a competitive market.

Myovant Plans Q4 Uterine Fibroid Drug Filing In A Showdown With AbbVie

A second Phase III trial testing relugolix met its primary endpoint, putting Myovant in a tight race with AbbVie to bring the first drug to market for women with uterine fibroids.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141209

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel